2:31 PM
 | 
Jan 06, 2017
 |  BC Week In Review  |  Company News  |  Deals

Bird Rock, J&J deal

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson partnered with Bird Rock to develop the biotech's namacizumab. The antibody targets cannabinoid CB1...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >